Development and Biological Evaluation of a Novel Aurora A Kinase Inhibitor

ChemBioChem ◽  
2009 ◽  
Vol 10 (3) ◽  
pp. 464-478 ◽  
Author(s):  
Teresa Sardon ◽  
Thomas Cottin ◽  
Jing Xu ◽  
Athanassios Giannis ◽  
Isabelle Vernos
Keyword(s):  
Kinase Inhibitor ◽  
Biological Evaluation ◽  
Aurora A Kinase ◽  
Aurora A

scholarly journals Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies

2017 ◽  
Vol 36 (2) ◽  
pp. 240-247 ◽  
Author(s):  
Xiaofei Zhou ◽  
John Nemunaitis ◽  
Shubham Pant ◽  
Todd M. Bauer ◽  
Manish Patel ◽  
...  
Keyword(s):  
Kinase Inhibitor ◽  
Qtc Interval ◽  
Aurora A Kinase ◽  
Aurora A ◽  
Advanced Malignancies

scholarly journals The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent

Cell Cycle ◽  
2012 ◽  
Vol 11 (4) ◽  
pp. 807-817 ◽  
Author(s):  
Jayasree S. Nair ◽  
Alan L. Ho ◽  
Gary K. Schwartz
Keyword(s):  
Kinase Inhibitor ◽  
Aurora A Kinase ◽  
Aurora A

scholarly journals Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

2018 ◽  
Vol 24 (24) ◽  
pp. 6150-6159 ◽  
Author(s):  
Kevin R. Kelly ◽  
Jonathan W. Friedberg ◽  
Steven I. Park ◽  
Kevin McDonagh ◽  
John Hayslip ◽  
...  
Keyword(s):  
Phase I ◽  
B Cell ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Aurora A Kinase ◽  
Aurora A ◽  
Aggressive B Cell Lymphoma

scholarly journals Deep and Prolonged Response to Aurora A Kinase Inhibitor and Subsequently to Nivolumab in MYCL1-Driven Small-Cell Lung Cancer: Case Report and Literature Review

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Bhaskar C. Kolla ◽  
Emilian Racila ◽  
Manish R. Patel
Keyword(s):  
Kinase Inhibitor ◽  
Small Cell Lung Carcinoma ◽  
Significant Proportion ◽  
Small Cell ◽  
Cancer Case ◽  
Aurora A Kinase ◽  
Aurora A ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Tumor Immune Evasion

Small-cell lung carcinoma (SCLC) is one of the most aggressive solid tumors, and the prognosis has not improved significantly in 25 years. Despite a recent understanding of the genomic aberrations seen in SCLC, these insights have not led to any breakthroughs in treatment. We present a patient with SCLC harboring a novel MYCL1 fusion protein who experienced a prolonged disease course due to the use of Aurora A kinase inhibitor and subsequently nivolumab. MYC family genes are master regulators of several cellular pathways including proliferation, differentiation, and apoptosis and recently have been shown to be involved in tumor immune evasion. Large studies have shown that a significant proportion of patients with SCLC have amplification or overexpression of MYC family genes. Preclinical data have exposed vulnerability of MYC-driven tumors to Aurora kinase inhibitors, bromodomain and extraterminal domain inhibitors, and recently to immune checkpoint blockers. Further studies using these agents with selective enrolling of patients with MYC-altered tumors are warranted to exploit these vulnerabilities.

scholarly journals Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1‐Deficient Carcinoma

2018 ◽  
Vol 24 (2) ◽  
pp. 146-150 ◽  
Author(s):  
Theodoros Karantanos ◽  
Lisa Rooper ◽  
Youme Kang ◽  
Cheng Ting Lin ◽  
Pawla Wenga ◽  
...  
Keyword(s):  
Clinical Benefit ◽  
Kinase Inhibitor ◽  
Aurora A Kinase ◽  
Aurora A ◽  
Integrase Interactor 1

scholarly journals The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

2011 ◽  
Vol 15 (10) ◽  
pp. 2057-2070 ◽  
Author(s):  
Kevin R. Kelly ◽  
Jeffrey Ecsedy ◽  
Ernest Medina ◽  
Devalingam Mahalingam ◽  
Swaminathan Padmanabhan ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Kinase Inhibitor ◽  
The Novel ◽  
Aurora A Kinase ◽  
Aurora A

A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e13026-e13026 ◽  
Author(s):  
S. E. Minton ◽  
P. LoRusso ◽  
A. C. Lockhart ◽  
M. Saif ◽  
S. S. Krishnamurthi ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Advanced Solid Tumors ◽  
Aurora A Kinase ◽  
Aurora A
Sign in / Sign up

Export Citation Format

Share Document